Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

990
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
990
Management of Insomnia01:19

Management of Insomnia

788
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
788
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

1.9K
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
1.9K
Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

3.1K
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
3.1K
REM Sleep Behavior Disorder01:15

REM Sleep Behavior Disorder

2.9K
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
2.9K
Sedatives and Hypnotics Drugs: Benzodiazepines01:19

Sedatives and Hypnotics Drugs: Benzodiazepines

1.5K
Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) 2025 international guidelines for the management of patients with obsessive-compulsive disorder.

Journal of psychiatric research·2026
Same author

Rethinking how we educate our future physicians: the Queen's-Lakeridge Health Medical Degree Family Medicine program: an innovative approach to medical education.

Canadian medical education journal·2026
Same author

Neurobiological effects of microbial treatments within psychiatry: a systematic review.

Frontiers in psychiatry·2026
Same author

The association between body mass index and treatment outcomes in major depressive disorder: a CAN-BIND-1 study.

Journal of psychiatric research·2026
Same author

Lam Employment Absence and Productivity Scale (LEAPS): Analysis of the minimal clinically important difference (MCID) in patients with major depressive disorder using data from the CAN-BIND-1 study.

Journal of affective disorders·2026
Same author

One-Year Actigraphy Study of Sleep and Rest-Activity Rhythms as Markers of Relapse in Depression.

JAMA psychiatry·2026

Related Experiment Video

Updated: May 6, 2026

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

1.8K

Sleep architecture in ziprasidone-treated bipolar depression: a pilot study.

Anusha Baskaran1, Dave Summers, Stephanie Lm Willing

  • 1Centre for Neuroscience Studies, Queen's University, Providence Care, Mental Health Services, Kingston, Ontario, Canada.

Therapeutic Advances in Psychopharmacology
|October 30, 2013
PubMed
Summary

Adjunctive ziprasidone therapy improved sleep architecture in bipolar depression patients, enhancing sleep efficiency and reducing awakenings. This suggests a potential mechanism for ziprasidone

Keywords:
Atypical antipsychoticREMSWSbipolar depressionpolysomnographysleep architectureziprasidone

More Related Videos

A Chronic Sleep Fragmentation Model using Vibrating Orbital Rotor to Induce Cognitive Deficit and Anxiety-Like Behavior in Young Wild-Type Mice
06:23

A Chronic Sleep Fragmentation Model using Vibrating Orbital Rotor to Induce Cognitive Deficit and Anxiety-Like Behavior in Young Wild-Type Mice

Published on: September 22, 2020

5.3K
Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
05:59

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

3.0K

Related Experiment Videos

Last Updated: May 6, 2026

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

1.8K
A Chronic Sleep Fragmentation Model using Vibrating Orbital Rotor to Induce Cognitive Deficit and Anxiety-Like Behavior in Young Wild-Type Mice
06:23

A Chronic Sleep Fragmentation Model using Vibrating Orbital Rotor to Induce Cognitive Deficit and Anxiety-Like Behavior in Young Wild-Type Mice

Published on: September 22, 2020

5.3K
Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
05:59

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

3.0K

Area of Science:

  • Psychiatry
  • Sleep Medicine
  • Pharmacology

Background:

  • Bipolar depression significantly disrupts sleep architecture.
  • Understanding treatment effects on sleep is crucial for managing bipolar disorder.
  • Ziprasidone is an atypical antipsychotic used as augmentation therapy.

Purpose of the Study:

  • To investigate the impact of ziprasidone augmentation on sleep architecture in bipolar depression.
  • To assess changes in sleep parameters during acute and continuation treatment phases.
  • To evaluate effects on subjective sleep quality and illness severity.

Main Methods:

  • A double-blind, randomized, placebo-controlled pilot trial was conducted.
  • Participants had bipolar disorder with a current major depressive episode.
  • Sleep architecture was measured using polysomnography; illness severity and subjective sleep were also assessed.

Main Results:

  • Ziprasidone significantly improved REM latency, SWS duration, stage 2 sleep duration, total sleep time, sleep onset latency, number of awakenings, and sleep efficiency compared to placebo.
  • Clinical Global Illness Severity (CGI-S) and Hamilton Anxiety Rating Scale (HAMA) scores improved significantly with ziprasidone.
  • No significant differences were observed in HAM-D17, MADRS, or self-reported sleep quality.

Conclusions:

  • Adjunctive ziprasidone treatment positively alters sleep architecture in bipolar depression.
  • These sleep changes may contribute to ziprasidone's mechanism of action in treating bipolar depression.
  • Further research is warranted to explore these findings and their clinical implications.